Posts Tagged ‘NVGN’

NVGN mushrooms, CSCO popular, TSTY fails to rise

Monday, March 28th, 2011

Novogen Limited (Nasdaq: NVGN) vaulted an incredible 145.3% in price Monday afternoon to $2.60, on volume of four million shares, trampling over an average of less than 140,000 a day.

Cisco Systems Inc. (Nasdaq: CSCO) dealt in 30.9 million shares by post-lunch hour Monday, compared to a daily average of 71.5 million shares. CSCO shares sold for $17.31, or just 0.1% more than they closed on Friday, as CSCO showed up on a short list of “insanely cheap tech stocks” posted by the site known as Minyanville.

Tasty Baking Company (Nasdaq: TSTY) fell without a parachute Monday afternoon, losing 14.8% in price to $1.78. Volume of just over 209,000 more than doubled its daily average, after delaying the release of its annual report.

NVGN leaps, MU active, MCOX in doldrums

Monday, January 24th, 2011

Novogen Limited (Nasdaq: NVGN) shares accelerated 41.1 percent to $1.58, on 1.8 million shares, overwhelming a daily average of 42,778. Australia-based NVGN has a consumer healthcare business, providing research and development services to its 71.3-per-cent-owned subsidiary, Marshall Edwards, Inc.

Micron Technology Inc. (Nasdaq: MU) dealt in 48 million shares Monday, more than 50 percent better than its full-day average of 32.3 million. Share prices improved 1.9 percent to $10.02. Over the past 12 months, Micron Technology generated $2,483 million cash on net income of $1,801 million.

Mecox Lane Limited (Nasdaq: MCOX) sagged 9.6 percent to $5.56 Monday. Volume for the stock was 335,728 shares, rearing behind its daily average of 823,049, as the days wound down toward the deadline for plaintiff action in its upcoming lawsuit.

Buzz Stock of the Day – Novogen (NVGN)

Wednesday, July 8th, 2009

Shares of Australian pharmaceutical company Novogen Ltd. (Nasdaq: NVGN) continued their climb today after closing up 24 percent on the day yesterday.

Shares were up as much as 83 percent presumably another run on yesterday’s news that researchers found that the investigational anti-tumor drug, phenoxodiol, to be effective in killing cancer cells.
Phenoxodiol is licensed by Marshall Edwards (Nasdaq: MSHL), which is majority owned by Novogen Ltd.

The results make phenoxodiol a promising candidate for the treatment of pathologically activated lymphocytes such as those in acute lymphoid leukemia, or diseases driven by T-cell proliferation such as autoimmune diseases and graft-versus-host disease, according to an article published in the Haematologica Journal on June 16.